ProCE Banner Activity

CE / CME

CRE-ating Success: How I Use Rapid Diagnostic Tests to Manage Carbapenem-Resistant Enterobacterales Bacteremia

Clinical Thought

Read this case study to learn my approach to CRE infections, specifically NDM-producing Enterobacterales, including weighing treatment options based on patient- and infection-related considerations.

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 08, 2023

Expiration: December 07, 2024

Share

Faculty

Julie Ann Justo

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from bioMérieux, Inc.

bioMérieux, Inc.

Target Audience

This program is intended for infectious diseases physicians and pharmacists, as well as other healthcare professionals who provide care for patients with and/or at risk for CRE bacteremia.

Program Learning Goal

To improve learners’ knowledge and competence in the management of CRE bacteremia, including appropriate utilization of rapid diagnostic results and broad-spectrum β-lactam agents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify risk factors for CRE and mechanisms of resistance, including carbapenemase and non-carbapenemase resistance factors

  • Optimize utilization of broad-spectrum antimicrobial agents for patients with CRE bacteremia

  • Develop individualized treatment plans for patients with CRE bacteremia, accounting for factors such as source of infection and changing pharmacodynamics

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Julie Ann Justo, PharmD, MS, FIDSA, BCPS

Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire

Julie Ann Justo, PharmD, MS, FIDSA, BCPS: consultant/advisor/speaker: Entasis Therapeutics, Gilead Sciences, Shionogi, Spero Therapeutics; stock/stock options: Vaxart. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 08, 2023, through December 07, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.25 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-315-H01-P 
Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.